Literature DB >> 33528236

Plan Type and Opioid Prescriptions for Children in Medicaid.

Jordan Banks1, Courtney Hill, Donald L Chi.   

Abstract

BACKGROUND: Opioids are generally an inappropriate acute pain management strategy in children, particularly because of the risk for diversion and subsequent misuse and abuse.
OBJECTIVES: To examine associations between Medicaid plan type [coordinated care organization (CCO), managed care (MC), fee-for-service (FFS)] and whether a child received an opioid prescription. RESEARCH
DESIGN: Secondary analysis of Oregon Medicaid data (January 1, 2016 to December 31, 2017).
SUBJECTS: Medicaid-enrolled children ages 0-17 (N=200,169). MEASURES: There were 2 outcomes: whether a child received an opioid prescription from (a) any health provider or (b) from a visit to the dentist. Predictor variables included Medicaid plan type, age, sex, race, and ethnicity.
RESULTS: About 6.7% of children received an opioid from any health provider and 1.2% received an opioid from a dentist visit. Children in a CCO were significantly more likely than children in a MC (P<0.01) or FFS (P=0.02) plan to receive an opioid from any health provider. Children in a CCO were also significantly more likely than children in MC or FFS to receive an opioid from a dentist visit (P<0.01).
CONCLUSIONS: Pediatric opioid prescriptions vary by plan type. Future efforts should identify reasons why Medicaid-enrolled children in a CCO plan are more likely to be prescribed opioids.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33528236      PMCID: PMC8026560          DOI: 10.1097/MLR.0000000000001504

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   3.178


  33 in total

1.  Missing covariate data in medical research: to impute is better than to ignore.

Authors:  Kristel J M Janssen; A Rogier T Donders; Frank E Harrell; Yvonne Vergouwe; Qingxia Chen; Diederick E Grobbee; Karel G M Moons
Journal:  J Clin Epidemiol       Date:  2010-03-24       Impact factor: 6.437

2.  Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing.

Authors:  Christopher M Jones; Peter G Lurie; Douglas C Throckmorton
Journal:  JAMA Intern Med       Date:  2016-03       Impact factor: 21.873

3.  A performance improvement prescribing guideline reduces opioid prescriptions for emergency department dental pain patients.

Authors:  Timothy R Fox; James Li; Sandra Stevens; Tracy Tippie
Journal:  Ann Emerg Med       Date:  2013-01-30       Impact factor: 5.721

4.  Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007-2012.

Authors:  Benjamin Levy; Leonard Paulozzi; Karin A Mack; Christopher M Jones
Journal:  Am J Prev Med       Date:  2015-04-18       Impact factor: 5.043

Review 5.  Applications of multiple imputation in medical studies: from AIDS to NHANES.

Authors:  J Barnard; X L Meng
Journal:  Stat Methods Med Res       Date:  1999-03       Impact factor: 3.021

6.  Recommendations for third molar removal: a practice-based cohort study.

Authors:  Joana Cunha-Cruz; Marilynn Rothen; Charles Spiekerman; Mark Drangsholt; Lyle McClellan; Greg J Huang
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

7.  Patient Outcomes in a Medicaid Managed Care Lock-In Program.

Authors:  Theresa R F Dreyer; Thomas Michalski; Brent C Williams
Journal:  J Manag Care Spec Pharm       Date:  2015-11

Review 8.  Update on Analgesic Medication for Adult and Pediatric Dental Patients.

Authors:  Constantinos Laskarides
Journal:  Dent Clin North Am       Date:  2016-04

9.  Racial differences in opioid prescribing for children in the United States.

Authors:  Cornelius B Groenewald; Jennifer A Rabbitts; Elizabeth E Hansen; Tonya M Palermo
Journal:  Pain       Date:  2018-10       Impact factor: 7.926

10.  Impact of a Mandatory Prescription Drug Monitoring Program on Prescription of Opioid Analgesics by Dentists.

Authors:  Linda Rasubala; Lavanya Pernapati; Ximena Velasquez; James Burk; Yan-Fang Ren
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.